Member Info for JustHereForHemo

I'm still bitter I lost lol, I had a dream it was Monday morning and 7am red dot was waiting!!! I assumed it was the 22nd.... but... honestly though board is much too busy now for guess the date bingo, it was dead and made for a bit of fun, but everyone is starting to arrive now that hemo are getting serious

I found it quite funny that most references I have seen, including the famous Zak Mir, have attributed the recent gains to the patent grant for CDX and NOT to the impending IND approval from the FDA. Just goes to show how few know what's actually happening here!

Moor, dw, the reference to death spiral refers to a previous disastrous mistake here, vlad won't repeat it. The 2 year blackout discussed would be very positive

£10mil at 6p to prevail and investors with a 2 year blackout period on condition that FDA lift clinical hold. Pure guess/speculation. Based on discount valuation agreed by Prevail when they did the last placing, the timing of that presentation with investors, timeline of the clinical hold and what's been approved at the agm and allowed by the main market. So a guess.... but an educated one.

PIPE with 2 year lock in sounds FANTASTIC. It's the discount placing to the twitter traders who have been free to troll and short the sp down the past few years which has been so destructive. 2 year lock in with enough cash to last a few years would be incredible.

It's comical and IMO reasonable odds alot of the nonsense is just fake :p

But? We are too close to IND so it ain't going to work. OFCOURSE some sold, they saw RNS and sold and they want in again cheaper before IND, unlucky lol. This is nor an update on in vivo results, or an investor presentation. This is permission from the FDA to start clinical trials, and its on THEIR timetable not Vlads. So genuinely, good luck traders, good luck! Cus IMO your going to need it 😂🤣😂🤣😂🤣

Someone please pass the popcorn! And please dont report this thread I really want to see where it goes! :-D

It is an interesting day to watch, bound to be people fighting the urge to sell/try a trade. Traditionally an RNS in Hemo has been a sell trigger for many who then expect a few weeks before the next update to buy back cheaper. For many, as we have seen today, its probably a muscle memory reflex and they just HAD to sell. But you can also feel the urge to hold and buy :P Todays RNS was mandatory, it came from the Patent office and would be made public anyway so Vlad could not delay release. Likewise, the lifting of Clinical Hold, that comes from the FDA, it 100% is market sensitive so Vlad cannot control when that will be RNS;ed it will happen when the FDA tell him or shortly after.

So how do people trade that lol? But again, it was 10% up and some traders only want that 10% :P Quite a dilemma for some! :P

Exactly, Lets be mean and call it what it is, CAR-T is a sacrificial pig. It is a big juicy "in vogue" hip, modern, current must have treatment. It commands fees in the 100s of thousands PER patient and licencing deals for it are 100s of millions up to around 1bn.

CAR-T will get into the clinic and when Vlad proves it works he will offer that suckler up on the stone table right beside Aslan and use the spoils from that to pay for CDX and CBR development.

EFM, correct, the standard treatment today is Chemotherapy followed by BMT, CDX does not do away with the need for BMT but it does remove the need to undergo chemotherapy. Hu-PHEC was and could in future be the perfect partner to CDX as it allows BMT without needing a third party to donate bone marrow. In terms of the range of indications listed in the patent yes you are correct its much bigger than AML, from memory AML Was chosen because it was so hard to cure, the survival rate was so low and the need for a cure was so pressing. This has a number of benefits, in particular the R/R AML that Hemo are targeting has a small number of new cases per year, 500 I believe? So it falls under:

https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program

Read the link, but basically, quicker to market, more support, less hurdles. Once CDX is approved for AML its much easier to run trials for other conditions like autoimmune conditions. It can also then potentially be prescribed for off label use.

Basically the target market for CDX is HUGE, and because it is not patient specific/off the shelf it is cheaper, easier to distribute, scale etc. Might not be as good as HEMO-CAR-T if you have AML.... But if it costs half the price and you can deliver to 10x more patients? Which one are the insurance companies more likely to go with?

Vlad cannot control the USPO, just like cannot control the FCA.

I realise we are all focused on CAR-T, and rightly so, but it is worth considering any potential impact from todays RNS....

" CDX which remains one of our key product candidates for the future. "....

Brief recap, CDX is why I initially bought into Hemo back almost 6 years now, at the time they were aiming for clinical trials in 18 months targeting blood cancers and would hope to marry it with Hu-PHEC. CDX is basically a replacement for chemotherapy and radiotherapy. Much less toxic, removes most of the nasty side effects that come with blindly injecting the body with poison or radiation. Avct have taken a different approach and are trying to just make chemo safer, its a very similar market but different approach, NOT making a comment on which is better, just useful for comparison of valuations. The market is worth billions and today a large percentage of older or vulnerable patients are simply not able to tolerate chemo so just get palliative care and die. So the true market is even bigger IF CDX is safe for those patients.

A few years ago CDX appeared to be culminating with anticipation of licencing deals with Eli Lilly and the SP was pretty static at around 10p despite a nasty CLN in place at the time. Eli were not in a position to progress CDX at speed, did not want to go down the oncology route it was not their business model so they did not licence CDX from Hemo but instead on very favourable terms licenced their IP to Hemo allowing Vlad to package CDX and continue the work. Some time after this we were told that licencing talks were ongoing with a pharma for CDX but it was taking a back seat to CBR and CAR-T. And that is where we have remained... During meetings and interviews its been made clear that there are active talks, in printed reports its more vague such as: " We continue to explore potential partnership arrangements to take that forward."

No clear reasons have been given for why it has taken so long to progress HOWEVER 2 likely scenarios are:

1, Hemogenyx may need to match some funding in any partnership - A problem that goes away when CAR-T is clinical

2, Its possible the partner did not want to invest time or money when there was a chance the patent would be rejected.

Now the patent has been accepted?.... Anyway this is my only comment on the RNS today, focus is CAR-T for now but it is worthy to remember that HEMO-CAR-T is the SMALLEST of the pipeline candidates, CDX has the potential to be HUGE and today may very well unlock corporate actions in the very near future. CBR has the potential to be Microsoft... And still its ALL available for less than 50mil! Lol :P This SP wont last, its not sustainable.

We are actually getting close to a very interesting Share Price.... 4.3p.... We touched 4p today and with FOMO friday might very well get both feet above that before close of play..... 4.3p is a key price though because thats a 50mil mCap valuation.

Over the years we have had fund managers on this forum, I have spoken to a few of those financial publishers that cover stocks, in this sphere there is this 50mil minimum valuation before anyone will take you seriously. many funds and II's wont invest in a sub 50m mCap, many editors will not allow such small companies to be recommended. I guess the risk profile is just too great with such a small mCap, looks likely we will get above that level in the very near future, question is will more people then start to look and will those funds start to take a position in Hemo......

If the FDA dont approve the IND then SP tanks back to the low 2's maybe even high 1s. People are buying this because they believe Hemogenyx are about to go clinical. There is no debate or argument to be had, if they dont get approval then Hemo will have to raise cash to see them though to the re-re-submission.

HOWEVER

If Vlad having agreed the plan with the FDA to lift the Clinical Hold, knowing EXACTLY what they require, has submitted a response that does not deliver what he has promised to deliver? Then the SP would deserve to tank!

But at this point we have Penn, the expert advisors, we have Prevail, ALL will have had insight to the clinical hold response. Hemogenyx identified the one issue raised by the FDA BEFORE the FDA notified them, Hemogenyx came up with a robust plan to lift the hold that went further than the single issue raised by the FDA, the FDA APPROVED that plan and Hemogenyx have stated that they have done what was asked. On average 95% of IND applications go though without a hitch first time, we had a hitch, I have zero concerns that the FDA wont lift the CH.

If your asking who is selling? Who cares! Whoever it is is selling on news and 100% would sell on IND approval, let them sell now, on a patent lol! Cya traders 😆

:-D

Lol, pumpkin knows it's 30 calendar days 😆 and she has been very very quiet..... me thinks someone sold at 3p and never got a chance to get back in. 🙃

If people really want to trade and will only buy cheaper? Lol, good luck, I was happy to pay 3.4p today,more than I have paid in a very very long time. But let's be clear, hemo is massively undervalued.

Nice 500k buy just printed...

Side note, Remember HEMO-CAR-T is the SMALLEST part of the Hemogenyx Pipeline, its also the EASIEST to value and closest to clinical trials and most likely to be sold off. So with this in mind, I asked how much HEMO-CAR-T is worth:

Valuation Ranges:

Early Phase 1: $20 million - $75 million: AML being a high-unmet need disease with limited treatment options can justify a higher starting point than the general range.

Mid-Phase 1: $30 million - $150 million: Initial safety and efficacy data, especially against a difficult-to-treat cancer like AML, can significantly impact value.

Late Phase 1: $75 million - $300 million: Positive safety and efficacy signals showing promise for AML patients could lead to substantial investor interest.

Thats a 20-300m Valuation for HEMO-CAR-T ONLY in Phase 1... For a company with mCap of 35mil....

I love a good blue weekend, upbeat, people have a few days to find us and do some research, the shorts get VERY nervous and you can tell who is out/short because there will be some panic ridden posts on here. And Monday morning is a fantastic time for RNS.

Be different if we were waiting for drilling results on a mining stock and it was 50:50 or something. But we are waiting on the FDA to respond to a response to clinical hold where the FDA already did a full review, already said they found only one issue, already agreed with Hemogenyx a plan to lift the clinical hold and Hemogenyx have already confirmed they did all they were asked for and have done the required testing. Waiting with Hemogenyx is 90% excitement, 8% frustration and about 2% nervousness. Just aslong as we dont get "the RNS" at like 4.01pm on a friday like we have in the past!!!!

Looking forward to it :-) Ideal scenario (And from what I hear very possible)

FDA let Hemo know tomorrow but Vlad does not RNS until 7am monday morning

FOMO Friday and we hit 4p

Shorts stay open over the weekend.

That would leave me requiring new boxers monday morning.

Period of consolidation followed by a bit of a shake to rinse out the weak hands and any stops then move it up. If it let the shorts out without losing their shirts then I am not impressed, IF however an RNS were now to drop we would be launching from a more stable base so all good :-)